Brief: Passage Bio Announces Positive Interim Data And Advances Phase 1/2 Trial Of Pbgm01 In Gm1 Gangliosidosis

Passage Bio

17/12/2021 13:46

Dec 17 (Reuters) - Passage Bio Inc  PASG.O :
    * PASSAGE BIO ANNOUNCES POSITIVE INTERIM SAFETY AND
BIOMARKER DATA
AND ADVANCES PHASE 1/2 TRIAL OF PBGM01 IN GM1 GANGLIOSIDOSIS
    * PASSAGE BIO INC - INDEPENDENT DATA MONITORING COMMITTEE
RECOMMENDS PROCEEDING WITH TWO ADDITIONAL PLANNED PATIENT
COHORTS
    * PASSAGE BIO INC -  POSITIVE SAFETY PROFILE, INCLUDING NO
SERIOUS
ADVERSE EVENTS IN IMAGINE-1 COHORT 1

Source text for Eikon:  ID:nGNX2rDYq2 
Further company coverage:  PASG.O 

 ((Reuters.Briefs@thomsonreuters.com;))